{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:41:20Z","timestamp":1793209280009,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41375-026-02948-9","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T12:01:11Z","timestamp":1775649671000},"page":"894-905","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting of ibrutinib resistance\u2013driving pathways by miR-28 in ABC-DLBCL"],"prefix":"10.1038","volume":"40","author":[{"given":"Emigdio","family":"\u00c1lvarez-Corrales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Moreno-Palomares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9508-2752","authenticated-orcid":false,"given":"Carmen","family":"G\u00f3mez-Escolar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2963-5769","authenticated-orcid":false,"given":"Mario","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udane","family":"Moral-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Laguna-Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Fuertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n S.","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Mur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"de Bonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Leiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Mart\u00ednez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Somoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena R.","family":"Ramiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3785-5868","authenticated-orcid":false,"given":"Virginia G.","family":"de Y\u00e9benes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"2948_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ajh.26151","volume":"96","author":"S Susanibar-Adaniya","year":"2021","unstructured":"Susanibar-Adaniya S, Barta SK. 2021 Update on Diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am J Hematol. 2021;96:617\u201329.","journal-title":"Am J Hematol"},{"key":"2948_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503\u201311.","journal-title":"Nature"},{"key":"2948_CR3","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396\u2013407.","journal-title":"N Engl J Med"},{"key":"2948_CR4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1146\/annurev-cancerbio-030518-055734","volume":"3","author":"RM Young","year":"2019","unstructured":"Young RM, Phelan JD, Shaffer AL, Wright GW, Huang DW, Schmitz R, et al. Taming the heterogeneity of aggressive lymphomas for precision therapy. Annu Rev Canc Biol. 2019;3:429\u201355.","journal-title":"Annu Rev Canc Biol"},{"key":"2948_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nature08638","volume":"463","author":"RE Davis","year":"2010","unstructured":"Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463:88\u201392.","journal-title":"Nature"},{"key":"2948_CR6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","volume":"171","author":"A Reddy","year":"2017","unstructured":"Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, et al. Genetic and functional drivers of diffuse large B-cell lymphoma. Cell. 2017;171:481\u201394.e15.","journal-title":"Cell"},{"key":"2948_CR7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41586-018-0290-0","volume":"560","author":"JD Phelan","year":"2018","unstructured":"Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, et al. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature. 2018;560:387\u201391.","journal-title":"Nature"},{"key":"2948_CR8","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","volume":"194","author":"RE Davis","year":"2001","unstructured":"Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194:1861\u201374.","journal-title":"J Exp Med"},{"key":"2948_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0779-z","volume":"17","author":"S Pal Singh","year":"2018","unstructured":"Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton\u2019s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17:57.","journal-title":"Mol Cancer"},{"key":"2948_CR10","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson WH, Young RM, Schmitz R, Yang YD, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922\u20136.","journal-title":"Nat Med"},{"key":"2948_CR11","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1182\/bloodadvances.2022009389","volume":"7","author":"PWM Johnson","year":"2023","unstructured":"Johnson PWM, Balasubramanian S, Hodkinson B, Shreeve SM, Sun S, Srinivasan S, et al. Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial. Blood Adv. 2023;7:2008\u201317.","journal-title":"Blood Adv"},{"key":"2948_CR12","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.ccell.2021.10.006","volume":"39","author":"WH Wilson","year":"2021","unstructured":"Wilson WH, Wright GW, Huang DW, Hodkinson B, Balasubramanian S, Fan Y, et al. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021;39:1643\u201353.e3.","journal-title":"Cancer Cell"},{"key":"2948_CR13","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.18.02403","volume":"37","author":"A Younes","year":"2019","unstructured":"Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, et al. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2019;37:1285\u201395.","journal-title":"J Clin Oncol"},{"key":"2948_CR14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/imr.12792","volume":"291","author":"RM Young","year":"2019","unstructured":"Young RM, Phelan JD, Wilson WH, Staudt LM. Pathogenic B-cell receptor signaling in lymphoid malignancies: new insights to improve treatment. Immunol Rev. 2019;291:190\u2013213.","journal-title":"Immunol Rev"},{"key":"2948_CR15","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/leu.2017.110","volume":"31","author":"D Jones","year":"2017","unstructured":"Jones D, Woyach JA, Zhao W, Caruthers S, Tu H, Coleman J, et al. C2 domain mutations co-occur with and resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment. Leukemia. 2017;31:1645\u20137.","journal-title":"Leukemia"},{"key":"2948_CR16","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","volume":"370","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, et al. Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib. New Engl J Med. 2014;370:2286\u201394.","journal-title":"New Engl J Med"},{"key":"2948_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood-2015-02-626846","volume":"126","author":"TM Liu","year":"2015","unstructured":"Liu TM, Woyach JA, Zhong YM, Lozanski A, Lozanski G, Dong S, et al. Hypermorphic mutation of phospholipase C, \u03b32 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. Blood. 2015;126:61\u20138.","journal-title":"Blood"},{"key":"2948_CR18","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa2114110","volume":"386","author":"E Wang","year":"2022","unstructured":"Wang E, Mi XL, Thompson MC, Montoya S, Notti RQ, Afaghani J, et al. Mechanisms of resistance to Noncovalent Bruton\u2019s tyrosine kinase inhibitors. New Engl J Med. 2022;386:735\u201343.","journal-title":"New Engl J Med"},{"key":"2948_CR19","doi-asserted-by":"crossref","unstructured":"Liu X, Lin YF, Zhuang QQ, Deng HR, Liu AC, Sun J. BTK inhibitors resistance in B cell malignancies: mechanisms and potential therapeutic strategies. Blood Rev. 2025;71:101273.","DOI":"10.1016\/j.blre.2025.101273"},{"key":"2948_CR20","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1158\/2643-3230.BCD-21-0063","volume":"2","author":"AL Shaffer 3rd","year":"2021","unstructured":"Shaffer AL 3rd, Phelan JD, Wang JQ, Huang D, Wright GW, Kasbekar M, et al. Overcoming acquired epigenetic resistance to BTK inhibitors. Blood Cancer Discov. 2021;2:630\u201347.","journal-title":"Blood Cancer Discov"},{"key":"2948_CR21","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2023.12.019","volume":"42","author":"JD Phelan","year":"2024","unstructured":"Phelan JD, Scheich S, Choi J, Wright GW, Haupl B, Young RM, et al. Response to Bruton\u2019s tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy. Cancer Cell. 2024;42:238\u201352 e9.","journal-title":"Cancer Cell"},{"key":"2948_CR22","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.cell.2012.04.005","volume":"149","author":"MS Ebert","year":"2012","unstructured":"Ebert MS, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. Cell. 2012;149:515\u201324.","journal-title":"Cell"},{"key":"2948_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.660450","volume":"12","author":"T Fuertes","year":"2021","unstructured":"Fuertes T, Salgado I, de Yebenes VG. microRNA fine-tuning of the germinal center response. Front Immunol. 2021;12:660450.","journal-title":"Front Immunol"},{"key":"2948_CR24","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.it.2020.08.006","volume":"41","author":"T Fuertes","year":"2020","unstructured":"Fuertes T, Ramiro AR, de Yebenes VG. miRNA-based therapies in B cell non-Hodgkin Lymphoma. Trends Immunol. 2020;41:932\u201347.","journal-title":"Trends Immunol"},{"key":"2948_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203\u201322.","journal-title":"Nat Rev Drug Discov"},{"key":"2948_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41392-025-02266-z","volume":"10","author":"J Song","year":"2025","unstructured":"Song J, Yang P, Chen C, Ding W, Tillement O, Bai H, et al. Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance. Signal Transduct Target Ther. 2025;10:219.","journal-title":"Signal Transduct Target Ther"},{"key":"2948_CR27","doi-asserted-by":"publisher","first-page":"8185","DOI":"10.1073\/pnas.1322466111","volume":"111","author":"C Schneider","year":"2014","unstructured":"Schneider C, Setty M, Holmes AB, Maute RL, Leslie CS, Mussolin L, et al. MicroRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas. Proc Natl Acad Sci USA. 2014;111:8185\u201390.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2948_CR28","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1182\/blood-2016-08-731166","volume":"129","author":"N Bartolome-Izquierdo","year":"2017","unstructured":"Bartolome-Izquierdo N, de Yebenes VG, Alvarez-Prado AF, Mur SM, Lopez Del Olmo JA, Roa S, et al. miR-28 regulates the germinal center reaction and blocks tumor growth in preclinical models of non-Hodgkin lymphoma. Blood. 2017;129:2408\u201319.","journal-title":"Blood"},{"key":"2948_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06178-0","volume":"14","author":"T Fuertes","year":"2023","unstructured":"Fuertes T, Alvarez-Corrales E, Gomez-Escolar C, Ubieto-Capella P, Serrano-Navarro A, de Molina A, et al. miR-28-based combination therapy impairs aggressive B cell lymphoma growth by rewiring DNA replication. Cell Death Dis. 2023;14:687.","journal-title":"Cell Death Dis"},{"key":"2948_CR30","doi-asserted-by":"publisher","first-page":"D1541","DOI":"10.1093\/nar\/gkaa1011","volume":"49","author":"S Rath","year":"2021","unstructured":"Rath S, Sharma R, Gupta R, Ast T, Chan C, Durham TJ, et al. MitoCarta3.0: an updated mitochondrial proteome now with sub-organelle localization and pathway annotations. Nucleic Acids Res. 2021;49:D1541\u2013D7.","journal-title":"Nucleic Acids Res"},{"key":"2948_CR31","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.1182\/bloodadvances.2020001685","volume":"4","author":"N Jain","year":"2020","unstructured":"Jain N, Singh S, Laliotis G, Hart A, Muhowski E, Kupcova K, et al. Targeting phosphatidylinositol 3 kinase-beta and -delta for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma. Blood Adv. 2020;4:4382\u201392.","journal-title":"Blood Adv"},{"key":"2948_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-018-2435-4","volume":"19","author":"M Foroutan","year":"2018","unstructured":"Foroutan M, Bhuva DD, Lyu R, Horan K, Cursons J, Davis MJ. Single sample scoring of molecular phenotypes. BMC Bioinform. 2018;19:404.","journal-title":"BMC Bioinform"},{"key":"2948_CR33","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41375-022-01749-0","volume":"37","author":"W Xu","year":"2023","unstructured":"Xu W, Berning P, Erdmann T, Grau M, Bettazova N, Zapukhlyak M, et al. mTOR inhibition amplifies the anti-lymphoma effect of PI3Kbeta\/delta blockage in diffuse large B-cell lymphoma. Leukemia. 2023;37:178\u201389.","journal-title":"Leukemia"},{"key":"2948_CR34","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.3324\/haematol.2011.050617","volume":"96","author":"S Mareschal","year":"2011","unstructured":"Mareschal S, Lanic H, Ruminy P, Bastard C, Tilly H, Jardin F. The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica. 2011;96:1888\u201390.","journal-title":"Haematologica"},{"key":"2948_CR35","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1182\/blood.2023020142","volume":"142","author":"Y Liu","year":"2023","unstructured":"Liu Y, Kimpara S, Hoang NM, Daenthanasanmak A, Li Y, Lu L, et al. EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma. Blood. 2023;142:1879\u201394.","journal-title":"Blood"},{"key":"2948_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2158-0","volume":"10","author":"I Kapoor","year":"2019","unstructured":"Kapoor I, Li Y, Sharma A, Zhu H, Bodo J, Xu W, et al. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K\/AKT activation in B-cell lymphoid malignancies. Cell Death Dis. 2019;10:924.","journal-title":"Cell Death Dis"},{"key":"2948_CR37","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1158\/1535-7163.MCT-16-0555","volume":"16","author":"HP Kuo","year":"2017","unstructured":"Kuo HP, Ezell SA, Schweighofer KJ, Cheung LWK, Hsieh S, Apatira M, et al. Combination of Ibrutinib and ABT-199 in diffuse large B-Cell lymphoma and follicular lymphoma. Mol Cancer Ther. 2017;16:1246\u201356.","journal-title":"Mol Cancer Ther"},{"key":"2948_CR38","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41401-020-00505-3","volume":"42","author":"XT Zhang","year":"2021","unstructured":"Zhang XT, Hu XB, Wang HL, Kan WJ, Xu L, Wang ZJ, et al. Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma. Acta Pharmacol Sin. 2021;42:814\u201323.","journal-title":"Acta Pharmacol Sin"},{"key":"2948_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55223-9","volume":"16","author":"F Millozzi","year":"2025","unstructured":"Millozzi F, Milan-Rois P, Sett A, Delli Carpini G, De Bardi M, Gisbert-Garzaran M, et al. Aptamer-conjugated gold nanoparticles enable oligonucleotide delivery into muscle stem cells to promote regeneration of dystrophic muscles. Nat Commun. 2025;16:577.","journal-title":"Nat Commun"},{"key":"2948_CR40","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s13346-022-01232-4","volume":"13","author":"R Zhang","year":"2023","unstructured":"Zhang R, Kiessling F, Lammers T, Pallares RM. Clinical translation of gold nanoparticles. Drug Deliv Transl Res. 2023;13:378\u201385.","journal-title":"Drug Deliv Transl Res"},{"key":"2948_CR41","doi-asserted-by":"crossref","unstructured":"Kumthekar P, Ko CH, Paunesku T, Dixit K, Sonabend AM, Bloch O, et al. A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. Sci Transl Med. 2021;13:eabb3945.","DOI":"10.1126\/scitranslmed.abb3945"},{"key":"2948_CR42","doi-asserted-by":"publisher","first-page":"4392","DOI":"10.1039\/D3NR05971E","volume":"16","author":"Z Tao","year":"2024","unstructured":"Tao Z, Zhang H, Wu S, Zhang J, Cheng Y, Lei L, et al. Spherical nucleic acids: emerging amplifiers for therapeutic nanoplatforms. Nanoscale. 2024;16:4392\u2013406.","journal-title":"Nanoscale"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02948-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02948-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02948-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:26:45Z","timestamp":1778048805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02948-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2948"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02948-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was funded by Spanish Ministerio de Ciencia e Innovaci\u00f3n grants PID2019-107551RB-I00\/AEI\/10.13039\/501100011033 and PID2022-137014OB-I00\/AEI\/10.13039\/501100011033\/ FEDER, UE to V.G.Y and PID2023-146982OB-I00, CEX2020-001039-S and\u00a0PID2024-159895OB-100\u00a0to A.S, IMDEA Nanociencia\u00a0and M.L, respectively. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovaci\u00f3n (MCIN) and the Pro CNIC Foundation), and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN\/AEI\/10.13039\/501100011033).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors confirm that all methods were performed in accordance with the relevant institutional guidelines and regulations. Tonsil samples included in this study were provided by the Hospital Universitario Puerta de Hierro Majadahonda (HUPHM)\/Instituto de Investigaci\u00f3n Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA) Biobank (Carlos III Health Institute Biobanks and Biomodels Platform) and were processed following standard operating procedures with the appropriate approval of the Ethics and Scientific Committees (AC0123-A-2023). Informed consent was obtained from all subjects. No identifiable images are included in this study. Animal procedures were conducted in accordance with EU Directive 2010\/63\/EU and Recommendation 2007\/526\/EC on the protection of animals used for scientific purposes, as implemented in Spanish law under Royal Decree 53\/2013. All protocols were reviewed by the CNIC Institutional Animal Care and Use Committee and approved by the Consejer\u00eda de Medio Ambiente, Administraci\u00f3n Local y Ordenaci\u00f3n del Territorio of the Comunidad de Madrid (PROEX 326.5\/21).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}